Injectable drug carrier comprising layered double hydroxide

Abstract

Provided is an injectable drug carrier including a non-toxic Layered Double Hydroxide (LDH) and pharmaceutically acceptable excipients. Provided is also a method of preparing the injectable drug carrier, the method including: synthesizing LDH with various compositions and controlling the size and shape of the LDH at a level that the LDH has no adverse effect in vivo. A solution obtained by dispersing the LDH in a solvent is injected in vivo. According to the method, nano-size LDH that does not affect a blood vessel in vivo can be synthesized. The LDH thus synthesized has no adverse effect in vivo even at a concentration of 400 mg/kg, and thus can contribute to establishment of a drug delivery system capable of improving the delivery efficiency of a specific drug.

1 . An injectable drug carrier comprising a non-toxic Layered Double Hydroxide (LDH) and a pharmaceutically acceptable excipients. 
   
   
       2 . The injectable drug carrier of  claim 1 , wherein the LDH has a particle size of  100  to  300  nm. 
   
   
       3 . A method of preparing the injectable drug carrier of  claim 1 , the method comprising:
 titrating a divalent and trivalent metal salts-containing aqueous solution with a base solution and incubating the resultant solution at room temperature or under hydrothermal synthesis condition to obtain LDH; and   controlling a particle size of the LDH.   
   
   
       4 . The method of  claim 3 , wherein the divalent metal is selected from the group consisting of magnesium (Mg 2+ ), calcium (Ca 2+ ), and zinc (Zn 2+ ), and the trivalent metal is selected from the group consisting of aluminum (Al 3+ ) and iron (Fe 3+ ). 
   
   
       5 . The method of  claim 3 , wherein the base solution is selected from the group consisting of sodium hydroxide (NaOH) and ammonia (N H 3 ). 
   
   
       6 . An injectable drug delivery system comprising the drug carrier of  claim 1  and a drug. 
   
   
       7 . The injectable drug delivery system of  claim 6 , wherein the drug is loaded into the drug carrier by ion exchange or coprecipitation. 
   
   
       8 . The injectable drug delivery system of  claim 6 , wherein the drug is methotrexate (MTX).